Literature DB >> 10652430

Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity.

K Ge1, J Duhadaway, D Sakamuro, R Wechsler-Reya, C Reynolds, G C Prendergast.   

Abstract

Oncogenic activation of MYC occurs often in breast carcinoma and is associated with poor prognosis. Loss or inactivation of mechanisms that restrain MYC may therefore be involved in tumor progression. In this study, we show that the MYC-interacting adaptor protein BIN1 is frequently missing in malignant breast cells and that this loss is functionally significant. BIN1 was expressed in normal and benign cells and tissues but was undetectable in 6/6 estrogen receptor-positive or estrogen receptor-negative carcinoma cell lines examined. Similarly, complete or partial losses of BIN1 were documented in 30/50 (60%) cases of malignant breast tissue analyzed by immuno-histochemistry or RT-PCR. Abnormalities in the organization of the BIN1 gene were apparent in only a minority of these cases, suggesting that most losses were due to epigenetic causes. Nevertheless, they were functionally significant because ectopic BIN1 induced programmed cell death in malignant cells lacking endogenous BIN1 but had no effect on the viability of benign cells. We propose that loss of BIN1 may contribute to breast cancer progression by eliminating a mechanism that restrains the ability of activated MYC to drive cell division inappropriately.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10652430

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  Characterization of bridging integrator 1 (BIN1) as a potential tumor suppressor and prognostic marker in hepatocellular carcinoma.

Authors:  Ke Pan; Xiao-ting Liang; Hua-kun Zhang; Jing-jing Zhao; Dan-dan Wang; Jian-jun Li; Qizhou Lian; Alfred E Chang; Qiao Li; Jian-chuan Xia
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

2.  BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.

Authors:  J Wang; Y Jia; S Zhao; X Zhang; X Wang; X Han; Y Wang; M Ma; J Shi; L Liu
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

3.  Regulation of E2F1-induced apoptosis by poly(ADP-ribosyl)ation.

Authors:  A Kumari; T Iwasaki; S Pyndiah; E K Cassimere; C D Palani; D Sakamuro
Journal:  Cell Death Differ       Date:  2014-09-26       Impact factor: 15.828

4.  Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin.

Authors:  Watson P Folk; Alpana Kumari; Tetsushi Iwasaki; Slovénie Pyndiah; Joanna C Johnson; Erica K Cassimere; Amy L Abdulovic-Cui; Daitoku Sakamuro
Journal:  J Biol Chem       Date:  2019-02-07       Impact factor: 5.157

Review 5.  Trial watch: IDO inhibitors in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Alexander Eggermont; Catherine Sautès-Fridman; Eric Tartour; Eugene P Kennedy; Michael Platten; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

6.  Dissecting BAR domain function in the yeast Amphiphysins Rvs161 and Rvs167 during endocytosis.

Authors:  Ji-Young Youn; Helena Friesen; Takuma Kishimoto; William M Henne; Christoph F Kurat; Wei Ye; Derek F Ceccarelli; Frank Sicheri; Sepp D Kohlwein; Harvey T McMahon; Brenda J Andrews
Journal:  Mol Biol Cell       Date:  2010-07-07       Impact factor: 4.138

7.  Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry.

Authors:  Hatem Soliman; Bhupendra Rawal; Jimmy Fulp; Ji-Hyun Lee; Alexis Lopez; Marylin M Bui; Farah Khalil; Scott Antonia; Harris G Yfantis; Dong H Lee; Tiffany H Dorsey; Stefan Ambs
Journal:  Cancer Immunol Immunother       Date:  2013-01-24       Impact factor: 6.968

Review 8.  BAR the door: cancer suppression by amphiphysin-like genes.

Authors:  George C Prendergast; Alexander J Muller; Arivudanambi Ramalingam; Mee Young Chang
Journal:  Biochim Biophys Acta       Date:  2008-09-18

Review 9.  Amphiphysin 2 (BIN1) in physiology and diseases.

Authors:  Ivana Prokic; Belinda S Cowling; Jocelyn Laporte
Journal:  J Mol Med (Berl)       Date:  2014-03-05       Impact factor: 4.599

10.  Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma.

Authors:  Hiroshi Urakawa; Yoshihiro Nishida; Hiroatsu Nakashima; Yoshie Shimoyama; Shigeo Nakamura; Naoki Ishiguro
Journal:  Clin Exp Metastasis       Date:  2009-10-06       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.